Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPOX02
2024-514560-10-00Phase 2Authorised
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab, capecitabine, irinotecan, oxaliplatin, fluorouracil and 2 more in colorectal cancer (CRC) and colon cancer (2 arms), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
bevacizumabcapecitabineirinotecanoxaliplatinfluorouracil
03
Conditions
colorectal cancer (CRC)colon cancer
Beyond the preview
Go deeper on 2024-514560-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514560-10-00.